sur MindBio Therapeutics (isin : CA60256C1086)
MindBio Therapeutics CEO Updates Shareholders on Clinical Trials Progress
VANCOUVER, BC / ACCESSWIRE / July 8, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), a biopharmaceutical company specializing in psychiatric medicine, provided an update to shareholders from CEO Justin Hanka.
MindBio is advancing two Phase 2B clinical trials for its lead drug, MB22001. The trials target Major Depressive Disorder and Advanced Stage Cancer-related depression and anxiety. Both trials are progressing well with scheduled patient dosing and are expected to finish in 2025.
A third Phase 2B clinical trial targeting Pre-Menstrual Syndrome and Pre-Menstrual Dysphoric Disorder has been approved to start dosing. Initial baseline data collection is planned for a smaller Phase 1/2a trial.
MindBio is notable for its sub-hallucinogenic microdosing model, differentiating it from peers. The company targets scalable, accessible, and affordable treatments and aims for a senior exchange listing after Phase 2B trials.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de MindBio Therapeutics